|
NEW YORK, NY--(MARKET WIRE)--Aug 17, 2007 -- Pluristem
Life Systems, Inc. (OTC BB:PLRS.OB
- News) (DAX: PJT),
a bio-therapeutics Company dedicated to the commercialization of
products for a variety of malignant, degenerative and auto-immune
indications, announced today it will present at the Noble Financial
Equity Conference on Monday, August 20, 2007 at 12:00 PM ET at the
Charleston Place Hotel in Charleston, South Carolina.
William R. Prather RPh, MD, Senior Vice President
Corporate Development, will give a 25-minute presentation regarding
Pluristem's history, technology and growth prospects. A question and
answer session will follow the presentation and one-on-one meetings with
investors will be held throughout the day.
The presentation with streaming video and PowerPoint
presentation will be webcast live on Noble Financial's conference
website at www.two-007.net. It will
also be archived on Pluristem's website at
www.pluristem.com. It is
recommended that interested parties register at least 15 minutes prior
to the start of the presentation to ensure timely access.
Pluristem Life Systems, Inc. (OTC BB:PLRS.OB
- News) is a
biotechnology company dedicated to the commercialization of allogeneic
stem cell therapy products for the treatment of several severe
degenerative, malignant and autoimmune disorders. The Company's first
planned product, PLX-BMT, targets a $2 billion market and intends to
resolve the global shortfall of matched tissue for bone marrow
transplantation by improving the engraftment of umbilical cord blood
(UCB). Pluristem's products are derived from mesenchymal stem cells
obtained from the placenta and expanded in the Company's proprietary
PluriX(TM) 3D bioreactor that imitates the natural microstructure of
bone marrow and does not require supplemental growth factors or
cytokines. Pluristem believes the resultant expanded cells are
multipotent and able to differentiate into a variety of different cell
types as well as being immune-privileged to protect the recipient from
immunological reactions that often accompanies transplantation.
Safe Harbor Statement
This press release contains statements, which may
constitute "forward-looking statements" regarding our intent, belief or
current expectations. Forward-looking statements in this release include
that PLX-BMT cells shows promise in improving the engraftment of umbilical
cord blood (UCB); has a potential market of $2 Billion; that the
Pluristem's cells can potentially result in beneficial therapies for a
number of serious diseases; and that our PLX cells may be the first
allogeneic, off-the-shelf product to treat this serious disease. Factors
that could prevent our forward-looking statements from being achieved
include that we may be unable to get regulatory approval for our
products; we may be unsuccessful in developing any products; our
technology may not be validated as we progress further and our methods
may not be accepted by the scientific community; we may be unable to
retain or attract key employees whose knowledge is essential to the
development of our products; unforeseen scientific difficulties may
develop with our process; results in the laboratory may not translate to
equally good results in real surgical settings; our patents may not be
sufficient to protect essential aspects of our technology; competitors
may invent better technology; our products may not work as well as hoped
or worse, our products may harm recipients; and we may not be able to
raise funds for development or working capital when we require it. As
well, our products may never develop into useful products and even if
they do, they may not be approved for sale to the public. For further
risk factors see the Company's latest 10-KSB filed with the SEC.
For more information visit our website at
www.pluristem.com
|
